Cancer Stem Cells “Hedge” Their Bets with Noncanonical Signaling

A collaborative team of scientists working as part of the OncoTrack project—an international consortium of scientists funded as part of the European Innovative Medicines Initiative—have recently discovered that cancer stem cells (CSCs) utilize a noncanonical signaling pathway, employing the Hedgehog protein and a positive regulator of WNT. The research team focused in on this pathway as a potential treatment option aimed at treating cancers via the targeted elimination of CSCs.